Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 5/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.51 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2188560 | 0.76 | ADORA1 (0.58) | CYP1A1CYP1A2CYP1B1KDM4EDCPS | |
| Hydrochloric Acid SCHEMBL11866131 | 0.74 | CYP1A1 (0.54) | CYP1A1CYP1A2CYP1B1KDM4EDCPS | |
| SCHEMBL31003506 | 0.74 | NPC1 (0.56) | KDM4EKMT2AALOX15ALDH1A1HPGD | |
| SCHEMBL11357725 | 0.73 | CYP1A1 (0.56) | CYP1A1CYP1A2CYP1B1DCPS | |
| SCHEMBL11374183 | 0.73 | CYP1A2 (0.52) | CYP1A1CYP1A2CYP1B1KDM4EDCPS | |
| SCHEMBL29232744 | 0.72 | CYP1A2 (0.53) | CYP1A1CYP1A2CYP1B1KDM4EKMT2A | |
| SCHEMBL31169377 | 0.72 | METAP1 (0.66) | CYP1A1CYP1A2CYP1B1KDM4EKMT2A | |
| SCHEMBL10705638 | 0.72 | METAP1 (0.66) | CYP1A1CYP1A2CYP1B1KDM4EKMT2A | |
| SCHEMBL30394017 | 0.72 | METAP1 (0.66) | CYP1A1CYP1A2CYP1B1KDM4EKMT2A | |
| SCHEMBL29593101 | 0.72 | CYP1A1 (0.77) | CYP1A1CYP1A2CYP1B1KMT2ADCPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687502-B2 | Substituted quinazoline or pyridopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-03-30 | — | — | US | claimed |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | MSD K.K. (JP) | 2008-02-07 | — | — | US | claimed |
| EP-1734040-A1 | SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-20 | — | — | EP | claimed |
| US-7687502-B2 | Substituted quinazoline or pyridopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | MSD K.K. (JP) | 2008-02-07 | — | — | US | disclosed |
| EP-1734040-A1 | SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | GCK, GCKR, PDXK | CYP1A1 1049/4885CYP1A2 618/4885CYP1B1 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.